QLUPOD AG: Qlupod AG to Be Listed Across the Entire Swiss Healthcare Market Through Galexis AG Starting April 1, 2026

Herisau (pta018/25.03.2026/11:08 UTC+1)

Qlupod AG announces that its products will be officially listed and distributed through

Galexis AG, Switzerland's leading healthcare logistics platform, starting April 1, 2026.

With this step, Qlupod gains access to one of the most important distribution channels in

the Swiss healthcare market. Through Galexis' distribution centers in Niederbipp and

Lausanne-Ecublens, more than 8,000 customers nationwide are supplied, including

pharmacies, drugstores, medical practices, hospitals, and care institutions.

The inclusion in the Galexis product portfolio represents a significant milestone for

Qlupod and enables the company to make its telemedicine healthcare platform

accessible to an even broader medical professional audience.

Through this listing, Qlupod will in the future not only be present in the electronics and

retail sectors but will also be directly available within the professional healthcare market

in Switzerland.

Strategic Milestone for Nationwide Market Coverage

With its integration into the Galexis distribution structure, Qlupod achieves near-

complete market coverage within the Swiss healthcare ecosystem. Qlupod's platform

solution, consisting of the Qlupod device as well as the applications QluApp, QluDoc, and

QluCare, enables the digital collection and transmission of important health data,

supporting both patients and medical professionals.

The QluPod was deliberately designed as a medical all-round device. It combines several

essential health measurements, including blood pressure, pulse, blood oxygen (SpO₂),

body temperature, and ECG, into a single system and can therefore replace up to five

separate devices that are commonly used individually in households. This creates

significantly broader usage possibilities for both patients and physicians in the areas of

prevention, monitoring, and telemedical care.

Particularly in private households, this form of health monitoring is becoming

increasingly important. Qlupod AG therefore pursues the vision that the QluPod will

become as common in households as a blood pressure monitor or thermometer, but with

significantly broader functionality.

In Switzerland, the QluPod may also be financially supported under certain conditions.

For example, Swica offers the possibility of partial reimbursement if the device is

prescribed by a physician. This particularly facilitates access to a comprehensive device

and modern telemedical monitoring for patients with chronic conditions.

Voices on the Partnership

Nikola Trajanov, Interim CEO of Qlupod AG, states:"The inclusion of our products in the Galexis portfolio is a decisive step for us. For

decades, Galexis has been a key partner within the Swiss healthcare system. Through

this listing, we can reach virtually the entire professional healthcare market in

Switzerland—from pharmacies and medical practices to hospitals. At the same time, with

QluPod we are bringing a device to market that combines multiple medical measurement

systems in a single product, creating new opportunities for prevention, telemedicine, and

patient monitoring."

Sandra Culjaga, Head of Distribution Switzerland at Qlupod, adds:

"The collaboration with Galexis enables us to efficiently integrate Qlupod into the

existing supply structure of the Swiss healthcare market. For pharmacies, physicians,

and other medical institutions, it will become significantly easier to obtain our solution

and incorporate it into their care concepts. At the same time, patients also benefit, as

access to modern telemedical monitoring becomes considerably easier."

Telemedicine Innovation for the Healthcare Market

The Qlupod combines multiple vital measurements within a single device and connects

them with a digital platform that structures health data and makes it available to

medical professionals. The goal is to efficiently connect prevention, monitoring, and

telemedical care.

With its inclusion in the Galexis network, Qlupod further expands its presence in the

healthcare sector and strengthens its position as a provider of integrated digital

healthcare solutions.

About Qlupod:

Qlupod AG is a start-up company in the field of telemedicine and develops innovative

solutions to make patient care efficient and cost-effective. With the QluPod device and

the associated software, the company is endeavouring to shape the future of healthcare.

The offering is aimed at hospitals, care facilities, medical professionals and private

individuals who want to monitor their health independently.

For more information about Qlupod AG and our products, please visit our website at

www.qlupod.com.

Disclaimer:

This publication constitutes neither an offer to sell nor a solicitation to buy securities.

Insofar as this document contains forward-looking statements, these do not represent

facts and are characterised by the words "expect", "believe", "estimate", "intend", "aim",

"assume" and similar expressions. These statements express the intentions, opinions or

current expectations and assumptions of Qlupod AG and are based on current plans,

estimates and forecasts which Qlupod AG has made to the best of its knowledge, but do

not claim to be correct in the future. Forward-looking statements are subject to risks and

uncertainties that are difficult to predict and are generally beyond the control of QlupodAG. It should be noted that actual events or developments may differ materially from

the events and developments expressed or implied by such forward-looking statements.

(end)

Emitter:	QLUPOD AG Bahnhofstrasse 23 9100 Herisau Switzerland
Contact Person:	Nikola Trajanov
Phone:	+41 71 510 05 45
E-Mail:	ir@qlupod.com
Website:	qlupod.eu
ISIN(s):	CH1222316429 (Share)
Stock Exchange(s):	-
Other Stock Exchanges:	Regelmaessige Kursfeststellung Schweiz